Protein Kinase Inhibitors: all 15,766 studies that test it

Page 154 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00121264Phase 1
• The Effect of Fasudil on Vascular Function in HumansCompletedNCT00120718Phase 2
• Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006CompletedNCT00119639Phase 1
• Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00119249Phase 2
• Study of Oral AEE788 in Adults With Advanced CancerCompletedNCT00118456Phase 1
• Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal CancerCompletedNCT00118261Phase 1
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and EverolimusTerminatedNCT00117702Phase 2/3
• PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to ImatinibCompletedNCT00117299Phase 2
• Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)CompletedNCT00116935Phase 3
• Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2
• Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)CompletedNCT00116376Phase 1/2
• Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00114283Phase 2
• SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.CompletedNCT00113893Phase 2
• Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT00113347Phase 1
• BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
• Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid TumorsTerminatedNCT00112684Phase 1
• Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT00112632Phase 2
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00112476Phase 1
• Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)CompletedNCT00112372Phase 1
• Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast CancerCompletedNCT00111787Phase 2
• MK0457 in Patients With Leukemia (0457-003)CompletedNCT00111683Phase 1
• Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell CarcinomaCompletedNCT00111020Phase 3
• Research Study for Patients With Metastatic Renal Cell CarcinomaTerminatedNCT00110344Phase 2
• Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)CompletedNCT00110188Phase 2
• A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyCompletedNCT00109265Phase 2
• Enzastaurin to Treat Recurrent Brain TumorTerminatedNCT00108056Phase 1
• Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.CompletedNCT00107432Phase 2
• AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma MultiformeCompletedNCT00107237Phase 1/2
• Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal WomenCompletedNCT00107016Phase 2
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast CancerCompletedNCT00105950Phase 2
• Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.CompletedNCT00105092Phase 2
• Study of XL999 in Adults With Solid TumorsCompletedNCT00104117Phase 1
• BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
• S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach CancerCompletedNCT00103324Phase 2
• Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorCompletedNCT00103168Phase 3
• Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung CancerCompletedNCT00103051Phase 2
• A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast CancerTerminatedNCT00102895Phase 2
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaTerminatedNCT00101231Phase 1
• Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00101114Phase 2
• Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
• Gefitinib in Treating Patients With Locally Advanced Esophageal CancerCompletedNCT00100945Phase 2
• Phase I (PH I) Mad Refractory Solid Tumor StudyCompletedNCT00099606Phase 1
• MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)TerminatedNCT00099346Phase 1
• Lapatinib in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00099060Phase 1/2
• Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal WomenCompletedNCT00099008Phase 1
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00098631Phase 2
• Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNCT00098618Phase 2
• Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00098605Phase 2
• Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By SurgeryCompletedNCT00098579Phase 1
• Everolimus in Treating Patients With Stage IV MelanomaCompletedNCT00098553Phase 2
• Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00098540Phase 2
• CCI-779 and EKB-569 in Treating Patients With Advanced Solid TumorsCompletedNCT00098501Phase 1
• Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerWithdrawnNCT00098462Phase 1/2
• Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant PatientsCompletedNCT00098241Phase 3
• A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) PatientsCompletedNCT00098007Phase 3
• Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft VasculopathyCompletedNCT00097968Phase 3
• S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
• Sorafenib in Treating Patients With Metastatic Breast CancerCompletedNCT00096434Phase 2
• Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian CancerCompletedNCT00096395Phase 2
• Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast CancerTerminatedNCT00096369Phase 2
• CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096239Phase 2
• Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00095966Phase 2
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerTerminatedNCT00095693Phase 2
• Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00095680Phase 2
• Lapatinib in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedNCT00095667Phase 2
• BMS-599626 in Patients With Advanced Solid MalignanciesCompletedNCT00095537Phase 1
• BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid TumorsCompletedNCT00095459Phase 1
• Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorTerminatedNCT00095329Phase 1/2
• A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)CompletedNCT00095225Phase 2
• Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedNCT00094978Phase 1
• Study Evaluating AMG 706 in Subjects With Advanced Solid TumorsCompletedNCT00093873Phase 1
• Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal CancerTerminatedNCT00093652Phase 1/2
• Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
• Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerCompletedNCT00093626Phase 2
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
• PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00093600Phase 1
• Sorafenib in Treating Patients With Metastatic or Recurrent Prostate CancerCompletedNCT00093457Phase 2
• Safety of KAI-9803 for Injection With Angioplasty Following Heart AttackCompletedNCT00093197Phase 1/2
• Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)CompletedNCT00093080Phase 2
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
• Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCompletedNCT00092001Phase 2
• A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00091663Phase 3
• Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTerminatedNCT00091156Phase 3
• Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryTerminatedNCT00091078Phase 2
• Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung CancerWithdrawnNCT00090675Phase 3
• Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)CompletedNCT00089960Phase 2
• SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving MethotrexateCompletedNCT00089921Phase 2
• Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
• Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00088959Phase 1
• Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder CancerCompletedNCT00088946Phase 2
• Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)CompletedNCT00088283Phase 2
• PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
• Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)CompletedNCT00088192Not applicable
• Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00087867Phase 2
• Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)CompletedNCT00087763Phase 2
• Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)CompletedNCT00087451Phase 1

← Protein Kinase Inhibitors overview